Characterisation of tumour cells expressing NK marker genes, especially XCL1, is essential to uncover molecular mechanisms and pathways which may offer alternative therapeutic targets and candidate drugs for this subgroup of ESCC. This evidence concerns the gene XCL1 and esophageal squamous cell carcinoma.